Does Blue Cross of Idaho Cover Farxiga?

What Is Farxiga and Why Does Coverage Matter?

Farxiga (dapagliflozin) is an oral SGLT2 inhibitor manufactured by AstraZeneca. The FDA first approved it in January 2014 for type 2 diabetes, then expanded the label in 2020 to include heart failure with reduced ejection fraction, and again in 2021 for chronic kidney disease (CKD) regardless of diabetes status [1]. Because it now carries three distinct indications, insurance reviewers at Blue Cross of Idaho may evaluate coverage differently depending on which diagnosis appears on your prescription.

The drug's list price sits near $600 per month, which makes formulary placement a major financial variable. A Tier 2 placement could mean a $40 copay; a Tier 4 or non-formulary placement could mean $400 or more every 30 days.

The Three FDA-Approved Indications That Affect Coverage

Coverage decisions at Blue Cross of Idaho often track the FDA label closely. The three indications are:

• Type 2 diabetes (T2D): Dapagliflozin 5 mg or 10 mg daily to improve glycemic control.
• Heart failure with reduced ejection fraction (HFrEF): Dapagliflozin 10 mg daily, regardless of diabetes status, based on the DAPA-HF trial [2].
• Chronic kidney disease (CKD): Dapagliflozin 10 mg daily in adults with CKD at risk of progression, regardless of diabetes, based on the DAPA-CKD trial [3].

When your prescriber lists a heart failure or CKD diagnosis as the primary indication, the prior authorization requirements and step-therapy rules may differ from a straightforward T2D claim. Ask your prescriber to confirm which ICD-10 code appears on the authorization request.

Why SGLT2 Inhibitor Coverage Has Expanded

Payer coverage of SGLT2 inhibitors grew substantially after landmark outcomes data emerged. In DAPA-HF (N=4,744), dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) [2]. In DAPA-CKD (N=4,304), it reduced the composite kidney or cardiovascular endpoint by 39% (HR 0.61; P<0.001) [3]. Results of that magnitude pushed major payers, including Blue Cross affiliates, to add SGLT2 inhibitors to preferred formulary tiers for CKD and HF management.

How Blue Cross of Idaho Organizes Its Formulary

Blue Cross of Idaho (BCBSID) is the state's largest insurer, covering roughly 600,000 members through individual, small-group, large-group, and Medicare Advantage plans. Each plan product maintains its own formulary, so a member on the Blue Preferred PPO may see different tier placement than someone on the MyBlue Health plan or a Medicare Advantage product like BlueShield Secure.

Formulary Tiers at Blue Cross of Idaho

Most Blue Cross of Idaho commercial plans use a four- or five-tier structure:

| Tier | Drug Type | Typical Copay Range | |------|-----------|---------------------| | 1 | Preferred generics | $5, $15 | | 2 | Non-preferred generics / preferred brands | $20, $50 | | 3 | Preferred brands | $40, $120 | | 4 | Non-preferred brands | $80, $250 | | 5 | Specialty / non-formulary | $200, $500+ |

Farxiga most commonly appears at Tier 3 on BCBSID commercial plans as of 2025. On some Medicare Advantage plans, it appears at Tier 3 as well, but the specific dollar amount is set during annual plan negotiations and can change each October 15 during open enrollment.

How to Look Up Your Specific Plan's Formulary

The fastest way to confirm coverage is to use Blue Cross of Idaho's online formulary search tool at bcidaho.com. You will need your plan name and group number (both on your insurance card). Search for "dapagliflozin" as the generic name, because the tool may list it under either name depending on the plan year.

You can also call the Member Services number on the back of your card and ask the representative three specific questions:

1. Is dapagliflozin (Farxiga) on my formulary?
2. What tier is it placed on, and what is my copay or coinsurance?
3. Does my plan require prior authorization or step therapy for this drug?

Prior Authorization and Step Therapy Requirements

Prior authorization (PA) is one of the most common barriers BCBSID members encounter with Farxiga. The insurer may require your physician to document that you have tried and failed, or have a contraindication to, a lower-cost alternative before approving Farxiga.

What Step Therapy Usually Looks Like

For type 2 diabetes, Blue Cross of Idaho commercial plans frequently require documentation of an adequate trial of metformin (typically 500 to 2,000 mg/day for at least 90 days) before approving a branded SGLT2 inhibitor. If metformin is contraindicated due to CKD stage 3b or above (eGFR <45 mL/min/1.73m²), your physician can document that contraindication to bypass the metformin step.

For heart failure with reduced ejection fraction, the PA form typically asks for:

• Confirmed HFrEF diagnosis with LVEF 40% or below
• Current GDMT (guideline-directed medical therapy) regimen, including ACE inhibitor or ARB and a beta-blocker
• Prescriber attestation that dapagliflozin is being added per current ACC/AHA heart failure guidelines [4]

For CKD, reviewers commonly ask for a recent eGFR result (typically 25 to 75 mL/min/1.73m²) and a UACR (urine albumin-to-creatinine ratio) above 200 mg/g, consistent with the DAPA-CKD enrollment criteria [3].

How to Appeal a Denial

If Blue Cross of Idaho denies a prior authorization request for Farxiga, your prescriber can file a peer-to-peer review request within 10 business days of the denial notice. Idaho's independent external review law (Idaho Code Title 41, Chapter 57) gives members the right to request an independent review if an internal appeal fails. AstraZeneca's Patient Access team at 1-833-FARXIGA can also assist with appeal letter templates.

What Farxiga Costs at Blue Cross of Idaho Plans

Cost depends on three variables: formulary tier, deductible status, and whether a manufacturer savings card applies.

Costs Before and After Deductible

If your plan has a $1,500 annual deductible and you have not yet met it, you will typically pay the pharmacy's negotiated rate rather than a flat copay. That negotiated rate for Farxiga at most Idaho retail pharmacies runs between $500 and $580 for a 30-day supply, even with insurance applied pre-deductible.

Once the deductible is met, your cost drops to the plan's standard copay or coinsurance for Tier 3, which typically falls between $50 and $120 per month on commercial plans.

The AstraZeneca Savings Card

Commercially insured patients (not enrolled in Medicare, Medicaid, or any government-funded program) may use AstraZeneca's Farxiga Savings Card to pay as little as $10 per 30-day supply, up to a maximum benefit of $3,600 per calendar year. The card is available at farxiga.com/savings. Medicare Part D members are not eligible, but they may qualify for the AstraZeneca Patient Assistance Program (PAP) if household income falls at or below 400% of the federal poverty level.

The following decision framework helps patients and prescribers choose the right cost-reduction pathway based on plan type:

Step 1: Confirm whether Farxiga is on your formulary and at what tier. Step 2: If Tier 3 or below and you have commercial insurance, apply the AstraZeneca savings card immediately, reducing your cost to $10, $35/month in most scenarios. Step 3: If prior authorization is denied, initiate a peer-to-peer appeal within 10 days and request the AstraZeneca Bridge Therapy program to maintain supply during the appeal. Step 4: If you have Medicare Part D and face a coverage gap, apply to the AstraZeneca PAP or ask your prescriber about switching to empagliflozin (Jardiance) or canagliflozin (Invokana), which may sit on a more favorable tier in your specific Part D plan. Step 5: If all SGLT2 inhibitors are non-formulary, ask your prescriber whether a therapeutic substitution to an on-formulary SGLT2 inhibitor meets your clinical needs, since class-level cardiovascular and kidney outcomes data are broadly similar across approved agents [5].

Clinical Evidence Supporting Farxiga Coverage Decisions

Blue Cross of Idaho's medical policy reviewers evaluate coverage requests against published clinical evidence and major guideline recommendations. Understanding that evidence helps patients and prescribers submit stronger authorization requests.

Cardiovascular Outcomes

The DECLARE-TIMI 58 trial (N=17,160) evaluated dapagliflozin in patients with T2D and either established cardiovascular disease or multiple risk factors [6]. Over a median 4.2 years, dapagliflozin reduced the rate of hospitalization for heart failure or cardiovascular death by 17% compared with placebo (HR 0.83; 95% CI 0.73 to 0.95; P<0.001 for non-inferiority; P=0.005 for superiority on the HF/CV death endpoint) [6]. This trial is frequently cited in prior authorization appeals for patients with established cardiovascular disease.

Kidney Outcomes

DAPA-CKD enrolled 4,304 patients with CKD stages 2 to 4 and albuminuria regardless of diabetes status [3]. The trial was stopped early because dapagliflozin so clearly reduced the composite primary endpoint (sustained 50% or greater decline in eGFR, end-stage kidney disease, or death from kidney or cardiovascular causes) that continuation was deemed unethical. The 2022 KDIGO guidelines now recommend SGLT2 inhibitors as first-line add-on therapy for patients with CKD and eGFR of 20 mL/min/1.73m² or above [7].

Current Guideline Endorsements

The 2024 American Diabetes Association Standards of Care state: "In patients with type 2 diabetes and established or high risk for cardiovascular disease, heart failure, or chronic kidney disease, an SGLT2 inhibitor with proven cardiovascular benefit is recommended" [8]. That language gives prescribers a direct guideline citation to include in a prior authorization letter, which reviewers at Blue Cross of Idaho are trained to weigh heavily.

The 2022 ACC/AHA/HFSA Heart Failure Guidelines assign a Class I (Level of Evidence A) recommendation to SGLT2 inhibitors to reduce hospitalization and cardiovascular death in patients with HFrEF [4]. A Class I recommendation is the strongest possible endorsement in cardiology guidelines, and it is difficult for a payer to maintain a non-formulary or non-covered status for a drug that carries one.

Alternatives to Farxiga on Blue Cross of Idaho Formularies

If Farxiga is not covered or sits at an unfavorable tier on your plan, three main alternatives exist within the SGLT2 inhibitor class.

Other SGLT2 Inhibitors

Jardiance (empagliflozin): FDA-approved for T2D, HFrEF, heart failure with preserved ejection fraction (HFpEF), and CKD. The EMPEROR-Reduced trial (N=3,730) showed a 25% reduction in the composite of cardiovascular death or HF hospitalization [5]. On some Blue Cross of Idaho plans, empagliflozin sits at Tier 2 due to different formulary negotiations.

Invokana (canagliflozin): FDA-approved for T2D and CKD. The CREDENCE trial (N=4,401) showed a 30% reduction in the primary kidney composite endpoint in patients with T2D and CKD [9].

Generic dapagliflozin: As of early 2025, no FDA-approved generic dapagliflozin is commercially available in the United States. AstraZeneca's patent protection on Farxiga is expected to extend at least through 2028 for the primary compound patents.

Other Diabetes Drug Classes

If your prescriber and Blue Cross of Idaho agree that an SGLT2 inhibitor is not appropriate or cannot be authorized, GLP-1 receptor agonists represent the other major class with strong cardiovascular outcomes data. Semaglutide (Ozempic, Rybelsus) and liraglutide (Victoza) both carry cardiovascular risk reduction labeling and appear on most Blue Cross of Idaho formularies at Tier 3. Prior authorization requirements typically mirror those for Farxiga.

How to Submit a Prior Authorization Request

Your prescriber's office typically initiates the prior authorization, but you can help by gathering the following documents before the appointment:

• Your most recent HbA1c result and the date it was drawn
• Your most recent eGFR and UACR lab values (required for CKD indication)
• Your most recent echocardiogram or LVEF measurement (required for HF indication)
• A list of all diabetes, heart failure, or CKD medications you have tried in the past 12 months
• Documentation of any contraindications to metformin or other step-therapy agents

Blue Cross of Idaho typically responds to PA requests within 3 business days for non-urgent cases and 24 to 72 hours for urgent cases. Idaho state law requires the insurer to provide a written denial letter with a specific clinical rationale if the request is not approved.

Practical Steps to Get Farxiga Covered This Month

1. Look up your formulary at bcidaho.com or call Member Services before your prescriber submits the PA.
2. Ask your prescriber to document the specific indication (T2D, HFrEF, or CKD) with the corresponding ICD-10 code and the guideline citation that supports the prescription.
3. Apply for the AstraZeneca savings card at farxiga.com/savings the same day your prescription is sent to the pharmacy. The card works even if the PA is still pending, covering the first fill in some pharmacy scenarios.
4. If the PA is denied, request a peer-to-peer review within 10 business days and ask AstraZeneca's patient access line (1-833-FARXIGA) for a free 30-day bridge supply while the appeal is processed.
5. If the appeal fails, ask your prescriber whether empagliflozin at a lower tier meets the same clinical goals. EMPEROR-Reduced showed a hazard ratio of 0.75 for the primary HF endpoint, comparable to DAPA-HF's 0.74 [2][5].